Preeclamptic Patients and Pentraxin 3 & Lipoprotein-associated Phospholipase A2

Kanuni Sultan Suleyman Training and Research Hospital

Status: Completed

Conditions: Pre-Eclampsia

Treatments: Diagnostic Test: Lipoprotein-associated phospholipase A2 ; new biomarker; Diagnostic Test: Pentraxin 3 ; new biomarker

Study type: Observational

Funder types: Other

Identifiers

NCT04239352

ATADEK-2020/01

Details and patient eligibility

About

In particular, pentraxine 3 (PTX3) molecule was assumed to have a prognostic value in acute myocardial infarction.In patients affected by acute myocardial infarction, early plasma elevation of PTX3 appears to predict a worse outcome in these patients in the longer term.

The inflammatory basis of preeclampsia resembles an atherogenic process.It is planned to investigate the role of these two molecules in endothelial dysfunction typical of preeclampsia.

The level of circulating PTX3 and Lp-PLA2 in preeclamptic patients and their serum levels according to the severity of preeclampsia and presence of IUGR, and comparison with the control group without preeclampsia and It is planned to investigate the cut-off values and sensitivity and specificity of both molecules together and separately in preeclampsia.

Enrollment: 80 patients

Sex: Female

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• pregnant women diagnosed with preeclampsia; The blood pressure and proteinuria (at least ≥ 300 mg in urine for 24 hours) will be established before the 20th week of gestation in normotensive pregnancies with an interval of 6 hours.
• Those who have Grand mal convulsions; other causes of convulsions and exclusion of coma were defined as having seizures for the first time after 20 weeks of gestation and 48-72 hours after delivery.
• The diagnosis of HELLP syndrome will be confirmed by intravascular hemolysis. (Abnormal peripheral smear and / or abnormal bilirubin values), high liver enzymes (high serum aspartate transaminase levels [AST], alanine transferase [ALT] and lactate dehydrogenase [LDH] üst 2 upper level) and low platelet count (<100 000 / mm3)
• healthy pregnant women without additional disease for the control group

Exclusion criteria

• Maternal diabetes
• Kidney disease
• Cardiovascular disease
• Neurological disease
• drug use history
• Hematological and immunological disease
• The presence of any infection
• Fetal anomaly
• In utero dead fetus

Trial design

80 participants in 2 patient groups

healthy pregnant women

Description:

Blood samples taken from 40 healthy pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method. this group will be the control group.

Treatment:

Diagnostic Test: Pentraxin 3 ; new biomarker

Diagnostic Test: Lipoprotein-associated phospholipase A2 ; new biomarker

preeclamptic pregnant women

Description:

Blood samples taken from 40 preeclamptic pregnant women will be obtained by taking patient consent forms and storing their serum at -80 degrees. Then, serum Pentraxin 3 and Lp-PLA2 levels will be checked in these blood by ELISA method. this group will be the study group.

Treatment:

Diagnostic Test: Pentraxin 3 ; new biomarker

Diagnostic Test: Lipoprotein-associated phospholipase A2 ; new biomarker